{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-067767","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.451037+00:00","generated_at":"2026-05-18T06:45:14.518191+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Journey Medical expands Emrosi payer coverage to 65% of commercial lives from 29% in May 2025","bullets":["Emrosi now has pharmacy benefit coverage for 65% of 187 million U.S. commercial lives, up from 29% in May 2025.","Expanded coverage expected to drive further growth in total prescription demand for rosacea treatment.","CEO cites targeted contracting strategy, increasing prescription demand, and superior clinical data as drivers.","Emrosi is available by prescription at specialty pharmacy chains."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-067767","json":"https://secwatch.observer/filing/0001104659-25-067767.json","markdown":"https://secwatch.observer/filing/0001104659-25-067767.md","text":"https://secwatch.observer/filing/0001104659-25-067767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925067767/0001104659-25-067767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925067767/tm2520913d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:45:14.518191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}